Publications by authors named "M Ziaei"
Keratoconus is a multifaceted corneal ectatic disorder characterized by a range of genetic and environmental risk factors. While genetic predisposition significantly influences global disease prevalence rates as well as severity and progression rates, emerging evidence highlights the critical interplay between environmental factors and genetic susceptibility. This article provides a comprehensive overview of environmental risk factors implicated in the onset and progression of keratoconus.
View Article and Find Full Text PDFPurpose: To evaluate the repeatability of a pyramidal wavefront-based refraction (WFR) measurement and its agreement with dry autorefraction (DR), cycloplegic autorefraction (CR), and subjective refraction (SR) in myopic refractive surgery candidates.
Methods: One hundred eighty-nine eyes from 189 participants were evaluated. PERAMIS aberrometry (PERAMIS; SCHWIND eye-tech-solutions, Kleinostheim, Germany), DR, and CR, as well as SR, were completed for all candidates.
Article Synopsis
- The study highlights the economic burden of keratoconus on patients and society, focusing on lifetime costs and expenditures related to management and treatment.
- It involved a survey of 110 participants from Auckland, revealing low visual rehabilitation rates and significant direct and indirect costs estimated at NZD 30.9 million annually, with individuals facing an average lifetime out-of-pocket expense of NZD 79,254.
- The findings emphasize the need for better funding and support, as the financial implications of keratoconus can pose barriers to effective management for patients.
Purpose: To compare biometric and optical coherence tomography parameters as well as refractive status in preterm children aged 4-8 years with or without retinopathy of prematurity (ROP), and evaluate their correlations with age and gender-matched full-term children.
Methods: Retrospective comparative cohort study of four groups of children. Children with a history of preterm birth, including ROP who received intravitreal bevacizumab (IVB) treatment, children with a history of ROP that regressed without treatment and those with no history of ROP were compared to age and gender-matched full-term children as a control group.